Clinical Report: Treatment Response to Immune Checkpoint Inhibitors in EGFR-Mutant Lung Adenocarcinoma

Overview

This study evaluates a CT-based deep learning model for predicting treatment response in patients with EGFR-mutant lung adenocarcinoma after resistance to first-generation TKIs. The model demonstrated promising performance with AUCs of 0.885, 0.819, and 0.863 across different cohorts, as reported in the study.

Background

EGFR mutations are prevalent in lung adenocarcinoma, and resistance to first-generation TKIs presents significant treatment challenges. The efficacy of immune checkpoint inhibitors (ICIs) in this context is unpredictable, highlighting the need for reliable predictive tools. Current biomarkers are inadequate, as noted in the literature, necessitating the development of non-invasive methods to assess ICI benefit.

Data Highlights

Key Findings

• The study included 490 patients with complete CT imaging and treatment response labels.
• The deep learning model achieved an AUC of 0.885 in the training cohort.
• Model performance was validated with AUCs of 0.819 and 0.863 in two separate validation cohorts.
• Prospective validation and benchmarking against clinical variables are necessary before clinical implementation, as stated in the study.
• Current biomarkers for guiding ICI therapy in EGFR-mutant NSCLC are inadequate.

Clinical Implications

The findings indicate that a deep learning model may enhance the prediction of treatment responses in patients with EGFR-mutant lung adenocarcinoma after TKI resistance.

Conclusion

The CT-based deep learning model shows potential for predicting treatment responses in a challenging patient population, but further validation is required.

Related Resources & Content

1. ASCO AI in Oncology, ASCO, 2026 -- Improved Immunotherapy Response Prediction in NSCLC With Deep-Learning Radiomic Biomarker
2. Frontiers in Immunology, Frontiers, 2026 -- Predicting response to immunochemotherapy in EGFR-mutant lung adenocarcinoma after third-generation TKI resistance using CT radiomics-based habitat imaging
3. The ASCO Post, ASCO Post, 2026 -- Deep-Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC
4. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0 - PubMed
5. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer | Journal of Clinical Oncology
6. asco ai in oncology — Improved Immunotherapy Response Prediction in NSCLC With Deep-Learning Radiomic Biomarker
7. the asco post — Deep-Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC
8. The ASCO Post — Deep-Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC
9. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0 - PubMed
10. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer | Journal of Clinical Oncology
11. Efficacy of Adding Immune Checkpoint Inhibition to Chemotherapy, With or Without VEGF Inhibition, in Patients With Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis With Reconstructed Individual Patient Data - PMC